Cigarette Smoking and Adipose Tissue: The Emerging Role in Progression of Atherosclerosis

Zhiyan Wang, Di Wang, and Yi Wang

Department of Cardiology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200080, China

Correspondence should be addressed to Yi Wang: wangyipublic@hotmail.com

Received 9 June 2017; Revised 8 November 2017; Accepted 27 November 2017; Published 27 December 2017

Academic Editor: Arbi Pecani

Copyright © 2017 Zhiyan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Smoking is an established risk factor for atherosclerosis through several underlying pathways. Moreover, in the development of atherosclerotic plaque formation, obesity, defined as excess fat mass accumulation, also plays a vital role in dyslipidemia and insulin resistance. Substantial evidence shows that cigarette smoking induces multiple pathological effects in adipose tissue, such as differentiation of adipocytes, lipolysis, and secretion properties in adipose tissue. Therefore, there is an emerging speculation in which adipose tissue abnormality induced by smoking or nicotine is likely to accelerate the progression of atherosclerosis. Herein, this review aims to investigate the possible interplay between smoking and adipose tissue dysfunction in the development of atherosclerosis.

1. Introduction

Cardiovascular diseases (CVDs) are identified as the leading causes of death in many countries, in both developing world and industrialized regions [1], and these diseases include coronary artery diseases, ischemic stroke, and peripheral artery diseases. The basic pathology of the aforementioned diseases is the advancement of atherosclerosis (AS) leading to vascular stenosis and plaque rupture. Notably, it is estimated that approximately 11% of global cardiovascular deaths are attributed to smoking [1], indicating that smoking is one of the independent risk factors in AS. Recent papers have shown an increase in carotid artery intima-media thickness among currently smoking adolescents, which points to an early atherogenic remodeling of the vasculature in youth [2], further aggravating the global burden of disease. Therefore, a variety of studies have been dedicated to explore the underlying causes of smoking-induced atherogenesis.

Apart from cigarette smoking, obesity is another public health issue in that the worldwide prevalence of obesity has dramatically increased since 1980 [3]. Obesity, characterized as excessive adipose tissue, has a harmful effect on vascular function, and its associated comorbidities are prone to develop CVDs. Similar to smoking, obesity in childhood/adulthood and the long-term consequences of vascular injury can be clinically relevant [4]. The underlying mechanisms of adipose tissue in AS have been studied in recent years, while the accurate pathways remain to be elucidated.

In particular, in 2002, it has estimated that approximately 20% of US smokers, about 9 million people, were obese [5]. Several studies have reported that people with coexistence of obesity and current smoking habits show especially large risks for mortality related to CVDs and other diseases [6, 7]. Furthermore, a burgeoning body of studies has reported that cigarette smoking has a complicated effect on body weight and the function of adipose tissue [8–10]. Therefore, this specific interaction between cigarette smoking and adipose tissue in atherogenesis may represent a crucial target for future therapy. The objective of the present paper is to delineate the mechanisms through which exposure to chemicals in cigarette smoking affects the differentiated status and functions of adipocytes, which may contribute to AS.

2. Pathogenesis of Atherosclerosis: a Brief Overview

Accrued data have defined atherosclerosis as a chronic low-grade inflammation of the vasculature system characterized
by atherosclerotic plaque formation and rupture. Abnormal accumulation and retention of low-density lipoprotein (LDL) and lipoprotein remnants have been implicated as initial triggers [11]. Associated enzymes in the vessel wall have the ability to modify this LDL to oxidized LDL, which serve as inflammatory signals [12]. Inflammatory cells are subsequently recruited to the arterial wall, such as monocytes, which differentiate into macrophages and are, as a result, activated to engulf oxidized LDL via scavenger receptors, creating foam cells, which secrete chemokines and other kinds of cytokines that further create a vicious cycle, more immune cell infiltration, and activation [13]. Additionally, there is another possible pathway in which many of these lipid-rich macrophages undergo apoptosis and necrosis, releasing their contents into the extracellular space and then formatting a necrotic core. Proliferation and migration of vascular smooth muscle cells (VSMCs) also participate in the pathological process of plaques, resultantly stimulating the release of cytokines, such as interleukin-1, 8 (IL-1, 8) and interferon-γ (IFN-γ). Collectively, these various cascade reactions lead to fatty streak formation and followed advancement of plaques. Aside from immune cell entry into the plaque through the intima, immune cells are also observed in the outer part of the vessel wall, the adventitia, and perivascular adipose tissue (PVAT). Of note, collagenous conduits and vasa vasorum may bridge the communication between the intima and adventitia, which highlights the role of the adventitia in coordinating the immune response in AS [14]. Furthermore, due to absence of the fascia barrier between PVAT and adventitia, it seems possible that PVAT secretes various kinds of local adipokines and cytokines to interact with the adventitia [15]. As a result, PVAT and the adventitia have provided emerging insight on atherogenesis.

3. Smoking and Atherosclerosis: a Well-Known Mechanism

Cigarette smoke contains more than 4000 different components, which complicates the understanding of the potential mechanisms of tobacco-related diseases [16]. Among these constituents, nicotine has been identified as one of the most important ingredients that participate in vascular inflammation. Nicotine has been shown to increase physiological parameters, such as blood pressure and heart rate [17]. In addition, while binding with high-affinity nicotinic acetylcholine receptors (nAChRs), nicotine exerts several bioactive actions on different cellular effectors involved in plaque formation and progression [18]. According to a number of in vitro and clinical studies, there is strong evidence that exposure to cigarette smoking impairs the normal prosperity of endothelial cells, especially in the youth group [19]. Nicotine and the resulting increased oxidative stress induce vascular endothelial dysfunction via inhibition of the activation of endothelial nitric oxide synthase (eNOS) and decreasing the generation and bioavailability of nitric oxide (NO) [20]. Moreover, nicotine increases the expression of adhesion molecules on endothelial cells, namely, intracellular adhesion molecular-1 and E-selectin, as a result of enhanced attachment and transmigration of monocytes to the vessel wall [21]. Considering the types of inflammatory cells, a recent study has shown that nicotine upregulates CD36 expression in monocytes/macrophages via activation of nAChRs, facilitating to engulf the lipid particles by macrophages [22]. Macrophages stimulated by the treatment of nicotine secrete elevated inflammatory cytokines, namely, tumor necrosis factor-α (TNF-α), IL-1β, and chemokines, creating the proinflammatory microenvironment in the subendothelium [23]. Furthermore, it is shown that VSMCs undergo the contractile-to-synthetic transition, characterized by enhanced growth and migration of VSMCs, which contributes to foam cell formation [24]. Apart from the above alternations of cells, other substances and structures can be induced upon exposure of nicotine. For instance, under the treatment of nicotine, vasa vasorum has been shown to expand to intima plaque and the neovascularure is discovered in the plaque, one of the markers of the unstable plaques [18]. Finally, exposure to smoking results in platelet activation, stimulation of a coagulation cascade, and impairment of anticoagulative fibrinolysis, which, in turn, promotes pathological thrombus formation [25]. Overall, cigarette smoking or nicotine has multiple actions on the advancement of AS (see Figure 1).

Polycyclic aromatic hydrocarbons (PAHs), another class of compounds in cigarette smoke, also induce atherogenesis [26]. PAHs binding with aryl hydrocarbon receptor can downregulate the cholesterol efflux [26]. Other cigarette-derived substances also participate in various pathways to promote AS [27].

4. Adipose Tissue and Atherosclerosis

Obesity is characterized by excessive or abnormal accumulation of adipose tissue. The traditional roles of adipose tissue are to store free fatty acids after eating and release them in fasting state, which is sensitive to the regulation of insulin. Notably, it is now widely recognized that adipose tissue is not only a storage depot but also an active source of bioactive factors, such as adipokines, which influence lipid levels, inflammation, oxidative stress, insulin resistance, and AS [28]. There are various kinds of adipokines participating in the advancement of atheromas, the bioactive actions of which are shown in Table 1.

Accumulating evidence indicates that obesity leads to adipose tissue dysfunction, including adipocyte hypertrophy, enhanced inflammation, and impaired vascular structure and function [29]. In light of the wide distribution of adipose tissue in human bodies, adipose tissue has the ability to exert systemic effects on the cardiovascular risk factors and associated CVDs. Blood lipid abnormalities caused by excess adipose tissue are classical features of metabolic syndrome, such as the presence of small dense LDL particles, which in part induce the proinflammatory place within the vascular wall [30]. More importantly, adipose tissue dysfunction leads to an imbalance in the production of adipokines. When obesity is present, the main characteristics of adipokine concentration are identified as elevated levels of leptin, resistance, and TNF-α [31–33], in conjunction with a decline in production of adiponectin and omentin [34, 35]. According to Table 1, the imbalance of adipokines relevant to obesity
### Table 1: Adipokines and their bioactive functions associated with cardiovascular diseases.

| Adipokine | Bioactive functions associated with cardiovascular diseases | Reference |
|-----------|-----------------------------------------------------------|------------|
| Leptin    | Increase heart rate and elevate blood pressure level      | [82]       |
|          | Increase lipolysis in skeletal muscle and adipocytes      | [83]       |
|          | Increase reactive oxygen species secretion in endothelial cells, such as H$_2$O$_2$ and HO generation | [84] |
|          | Facilitate cholesterol accumulation in macrophages        | [85, 86]  |
|          | Promote the expression of matrix metallopeptidase-2 in VSMCs | [87] |
|          | Act on various types of immune cells to promote the release of proinflammatory cytokines | [81, 88] |
| Adiponectin | Reduce tissue triglyceride content and upregulate insulin sensitivity | [89] |
|          | Suppress endothelial cell apoptosis                        | [90]       |
|          | Suppress TNF-α-induced NF-κB activation to decrease the recruitment of monocytes | [91] |
|          | Inhibit the expression of scavenger receptors-A1 of macrophages and mediate polarization toward anti-inflammatory M2 phenotype | [80, 92] |
|          | Attenuate proliferation and migration of VSMCs             | [93]       |
| TNF-α    | Downregulate insulin resistance                            | [94]       |
|          | Increase expression of adhesion molecules                 | [95]       |
|          | Induce the migration and proliferation of VSMCs            | [96]       |
| Omentin  | Proangiogenic property and inhibition of vascular inflammation | [97, 98] |
|          | Promote NO production and its vasodilating effect of vascular | [99, 100] |
| Resistin | Subclinical marker of atherosclerosis                      | [101]      |
|          | Increase the levels of endothelin-1, VCAM-1, and CCL2      | [102]      |
|          | Promote foam cell formation by the dysregulation of scavenger receptors in macrophages | [103] |
| A-FEBP   | The major mediator of vulnerable plaque formation           | [104]      |
|          | Secrete more proinflammatory cytokines, such as TNF-α and CCL2 | [105] |
| Chemrin  | Magnify the functions of adhesion molecules                | [106]      |

VSMCs, vascular smooth muscle cells; TNF-α, tumor necrosis factor-alpha; NF-κB, nuclear factor-kappa B; NO, nitro oxide; VCAM-1, vascular cell adhesion molecule-1; CCL2, CC-chemokine ligand 2; A-FABP, adipocyte fatty acid binding protein.

---

**Figure 1:** Smoking-associated inflammatory response in artery walls. Smoking causes endothelial dysfunction with VSMCs phenotypic modulation. In addition, more macrophages are recruited and activated to secrete cytokines and chemokines. The resultant inflammatory response leads to atherosclerotic plaque formation and subsequent plaque rupture. TNF-α: tumor necrosis factor-α; IL-1, interleukin-1.
would, upon interaction with multiple vascular cells, deteriorate the formation and advancement of plaques. Additionally, adipose tissue inflammation appears to be of importance in AS. For example, patients with coronary artery diseases produce higher levels of proinflammatory cytokines (such as TNF-α, IL-6, and visfatin) in epicardial adipose tissue [36]. Additionally, obese adipose tissue contains more M1 type macrophages, mast cells, and neutrophils, through in situ proliferation and migration, thus augmenting proinflammatory responses [37]. Adipocytes seem to associate with certain immune cells through cytokine secretion and antigen presentation [37], which may synergistically accelerate the chronic inflammation in obese subjects.

Aside from systematic effects, adipose tissue may have crucial local actions in AS due to unique types of adipose tissue, namely, PVAT. Both visceral adipose tissue and PVAT are mainly made up of white adipose tissue, which is more relevant to metabolic syndrome. Functionally, it is widely accepted that PVAT has a mechanical role as a connective tissue to protect the vessels against adjacent tissue [38]. In addition, PVAT has been reported to produce a wide range of adipokines, similar to visceral adipose tissue to interact with correspondent intima and mediate the vascular inflammation. Of note, compared to adipocyte in other adipose tissues, PVAT adipocytes release more angiogenic factors including thrombospondin-1, CC-chemokine ligand 2 (CCL2), and hepatocyte growth factor to mediate vascular remodeling [39]. Finally, the vasa vasorum serves as a conducting tube that delivers blood components, local adipokines, and inflammatory cells from PVAT, which highlights the pathological characters of PVAT in the atherosclerotic process.

5. Link between Cigarette Smoking and Adipose Tissue in Atherogenesis

5.1. Nicotinic Receptors in Adipose Tissue. nAChRs are members of a family of ligand-gated, pentameric ion channels that are tightly arranged around a central pore [18]. nAChRs are divided into muscular (α1, β1, γ/ε1, and δ1) and neuronal AChRs (α2–α9 and β2–β4) [40]. Traditionally, the major biological force of these receptors is to mediate the effects of the endogenous neurotransmitter, acetylcholine, at neuromuscular junctions. In addition, nonneuronal cells may also express functional nAChRs. Apart from the above cells, several lines of evidence show that exogenous nicotine and other components of cigarette smoking have the ability to bind to high-affinity nAChRs on multiple cell types in the cardiovascular system, specifically endothelial cells and VSCMs, which thereby exert direct actions and other cellular effectors that participate in the atherosclerotic plaque formation and growth [18, 27]. Furthermore, the study by Liu et al. detected nAChR expression in adipocytes by a reverse transcriptase-polymerase chain reaction. Under the further analysis of subunits for nAChRs, they found α1-7, 9, 10, and β1-4 mRNAs expressed in adipocytes. Cancell et al. evaluated α7-nAChR expression levels in whole subcutaneous adipose tissue obtained from morbidly obese subjects and from normal weight healthy individuals, further indicating that this receptor modulates inflammatory gene expression in human adipocytes [41]. The existence of α7-nAChRs in adipose tissue may establish a potential connection between nicotine and adipose tissue in chronic low-grade inflammation, thereby affecting the course of AS. Accordingly, several basic studies are employed to clear out the accurate signal pathway underlying the bind with nicotine and nAChRs in adipocytes. For instance, Wu et al. suggested that nicotine has the capacity to react with white adipose tissue through α7-nAChRs and adenosine 5′-monophosphate-activated protein kinase (AMPK) [8]. It follows that α7-nAChRs play a fundamental role in the nicotine-induced abnormality within adipose tissue.

Apart from nAChRs, there is another receptor located on the surface of adipocytes, local β-adrenergic receptor, to stimulate lipolysis in adipose tissue by systemic infusion of nicotine [42]. Several chemicals mediate the nicotine effects on β-adrenergic receptor, such as the catecholamines epinephrine and norepinephrine and other metabolites. The nicotine-evoked catecholamine release in the brain tissue, such as the striatum and hypothalamus [43], is possibly mediated by β2 and β4 nAChRs [44]. The nicotine metabolite nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane, for example, can directly bind with β-adrenergic receptor to induce lung cancer, pancreatitis, and endothelial cell injury [45–47]. In both brown and white adipocytes, Cao et al. have found that there is the β-adrenergic/cAMP/PKA signaling pathway, participating in brown fat thermogenesis [48]. Furthermore, data from Fashauer et al. shows that in 3T3-L1 adipocytes, β-adrenergic stimulation exerts certain effects on the physical function of adipocytes [49]. Thus, the above interactions may bridge the connection between nicotine or nicotine metabolites and adipose tissue. However, the downstream effects of this signaling pathway remain elusive, lacking the direct evidence needed to determine the accurate mechanisms.

5.2. Alterations in Adipocyte Differentiation and Functions of Adipose Tissue

5.2.1. Smoking and Adipogenesis. In many populations, cross-sectional studies show that mean body mass (BMI) tends to be lower among smokers than nonsmokers. The underlying reason is the increase in metabolic rate induced by cigarette smoking. However, when using the waist circumference or waist-to-hip ratio instead of BMI, there is evidence suggesting that cigarette smoking is in favor of greater accumulation of visceral fat [50]. A rat experiment showed that maternal exposure to nicotine during lactation may promote obesity in adulthood, accompanied with higher central adiposity and hyperleptinemia [51]. An in vivo study using Sprague-Dawley rats shows that prenatal nicotine exposure led to an increase in epididymal white adipose tissue weight at weaning, and marked hypertrophy of adipocytes, with increased gene expression of proadipogenic transcription factors such as peroxisome proliferator-activated receptor-γ (PPAR-γ), resulting in increased body weight and fat deposition [52]. PPAR-γ is widely considered to be essential in inducing differentiation from preadipocytes to mature adipocytes. In
one animal study, the supraphysiological activation of PPAR-γ by troglitazone, a kind of PPAR-γ agonist, increases the number of small adipocytes, which in turn promotes a flux of free fatty acids (FFAs) from the liver and muscle into WAT, leading to the upregulation of insulin sensitivity at the expense of increased WAT mass [53]. This is consistent with other studies that have reported that PPAR-γ-deficient mice are protected against adipocyte hypertrophy and obesity induced by high-fat diet and aging [54]. Of particular interest, cells with a reduction in PPAR-γ2 expression caused by artificial zinc finger repressor proteins are unable to undergo adipogenic differentiation, thereby suggesting that PPAR-γ2 plays a central role in orchestrating the adipogenesis process [55]. Of note, PPAR-γ has been reported to have anti-inflammatory activity, but the specific role in adipocyte remains unclear. Given that the possible elevated expression of PPAR-γ is induced by nicotine, more research is needed to elucidate the “nicotine-PPAR-γ” axis in the development of adipogenesis (Figure 2).

In light of the underlying pathways to influence the activity of PPAR-γ, it is plausible that oxidative stress may have a certain role in mature adipocyte formation. Exposure of 3T3-L1 adipocytes to concentrations of nicotine ranging from 60 nM to 6 μM significantly increased the generation of reactive oxygen species (ROS) [56]. Additionally, female C57BL/6 mice, upon exposure to acute smoking showed increased activity of glutathione peroxidase in the inguinal adipose tissue, potential proving that oxidative stress was increased in adipose tissue [57]. Another model using α7-nAChR-specific lentivirus shRNA showed similar results [8], which emphasized the involvement of nAChRs on ROS production. Additionally, Lee et al. reported that ROS facilitate the cellular differentiation from 3T3-L1 preadipocytes to adipocytes by accelerating the mitotic clonal expansion, the second course of adipocyte differentiation, whereas an antioxidant treatment causes S-phase arrest [58]. Thus, nicotine may, in part, induce oxidative stress in adipose tissue contributing to the mature adipocyte.

Other substance from cigarette has also been investigated in several studies. In epididymal fat, chronic carbon monoxide also led to a significant decrease in adipocyte size and an increase in adipocyte number [59]. Additionally, through culturing the isolated adipocytes from mice adipose tissue, it was found that PAHs had the ability to increase the adipose tissue mass [60]. This may attribute to the PPAR activation of PAHs and their metabolites [61]. These adipogenesis disturbances may cause the abnormality of adipose tissue, such as enhanced lipolysis and dysfunction of adipokines secretion, which directly promotes cardiovascular diseases and worsen metabolic diseases and related risk factors, as Bays reviewed in detail [62].

5.2.2. Smoking and Lipid Metabolism. Exposure to cigarette smoke may break the balance of lipid levels through affecting the function of adipose tissue. This impaired state is commonly referred to as “dyslipidemia” and is considered to be the putative link between smoking and AS.

Considering smoking-induced dyslipidemia, the regulation of lipolysis in adipose tissue is the key event. Both clinical and animal studies found that nicotine can block phosphodiesterase activation to promote lipolysis and as a result increase the levels of circulating FFAs [8], which is consistent with the results from An et al. in 2007 [56]. Of great significance, intracellular enzyme hormone-sensitive lipase (HSL), which participates in the hydrolysis of triglyceride in adipocytes, is probably regulated by treatment of nicotine. β-Adrenergic receptor stimulation by catecholamines increases the level of cAMP and, ultimately, activates HSL [63]. Based on this, it is conceivable that via β-adrenergic receptors, smoking has an effect on the activation of HSL, producing elevated FFAs, which are synthesized into triglycerides through transportation into the liver and then secreted.
back into circulation as triglyceride-rich lipoprotein, forming the profile of dyslipidemia (Figure 2). In contrast, one kind of PAHs, benzo[a]pyrene, has a significant inhibitory effect on epinephrine-induced FFAs release [60]. It meant the complexity of the compounds of cigarette smoking, which need further studies to explore out.

5.2.3. Smoking and Endocrine Function of Adipose Tissue. As previously discussed, adipokines and cytokines secreted by adipose tissue participated in the inflammation within the artery wall. Recently, the aim of many studies is to investigate how cigarette smoking affects the secretion of adipokines, thus resulting in a deeper understanding of the relationship between smoking and adipose tissue mediated by adipokines in the advancement of atherosclerotic plaques. Next, we will explore the alterations of many crucial adipokines under exposure to cigarette smoke, such as adiponectin, TNF-α, and leptin, as well as adipose tissue inflammation.

(1) Adiponectin and TNF-α. Hypoadiponectinemia was often detected in smokers without sexual difference, which is an independent risk factor for diabetes and AS [64, 65]. In accordance with this, adiponectin levels in healthy Greek smokers were elevated 9 weeks after smoking cessation [66]. In 3T3-L1 adipocytes, Iwashima et al. found that incubation with nicotine significantly reduced adiponectin mRNA expression and adiponectin secretion with dose dependence [64]. Moreover, cultured adipocytes and the adipose tissue of wild-type mice exposed to cigarette smoke extract high-molecular-weight adiponectin and subsequently block its release [67], suggesting an inverse association between smoking and the level of adiponectin.

An increasing body of studies further investigates the potential mechanisms underlying smoking-induced low adiponectin concentration. Of great interest, data from β2-/- mice models have shown that the β2 nAChR subunit may reduce the expression levels of AdipoQ genes under chronic nicotine administration [68], thus decreasing the generation of adiponectin. The exact signaling pathway involved in this process, however, has yet to be fully elucidated. Moreover, the activation of β-adrenergic receptors might have similar effects on the production of adiponectin, via a marked depletion of tissue adiponectin mRNA and elevated secretion of immature 30 kDa form [69]. Research has shown that cAMP, the second messenger of β-adrenergic receptors, may act indirectly through enhanced synthesis of inhibitory protein to destabilize adiponectin mRNA [69].

Of note, it is widely recognized that there is a negative interaction between adiponectin and TNF-α, investigated by in vivo study from Maeda et al. [70]. In human epicardial adipose tissue, tobacco smoking induces elevated levels of TNF-α and IL-6, creating the proinflammatory profile [71]. In vitro experiments have shown that TNF-α stimulates nuclear factor-kappa B (NF-κB), PI-3 kinase, and jun-N-terminal kinase cascades, subsequently enhancing lipolysis in periadipocytes [72]. In contrast, nicotine was detected to reduce TNF-α production from rat adipocytes in a dose-dependent manner via nAChRs, while the underlying mechanism remains to be clarified [68, 73]. Consequently, further research should pay more attention to the nAChRs in adipocytes and adipose tissue macrophages, both of which are the main source of TNF-α and adiponectin.

(2) Leptin. Results from several studies show that nicotine has paradoxical effects on the secretion of leptin among smokers. As a result of maternal exposure to nicotine during lactation, offspring rats displayed the hyperlipemia phenotype and higher visceral and total body fat mass [51, 74]. In contrast, previous studies reported a negative trend between cigarette smoking and plasma leptin levels in both diabetic subjects and healthy subjects [75]. After BMI adjustment, smokers were found to have lower leptin concentrations, which is probably attributed to the indirect effects of elevated catecholamine levels, rather than nicotine [76]. Of particular significance, Perkins et al. found no difference in leptin concentration on smoking status after controlling for BMI and age, while leptin levels only in women increased after smoking cessation [77]. One putative cause for these different conclusions may be the lack of attention to ethnic differences and the varying quantity of cigarettes. More research is needed to elaborate on the association between leptin and smoking/nicotine.

(3) Adipose Tissue Inflammation. As previously discussed, adipose tissue inflammation plays a fundamental role in the progression of atherosclerotic plaques. Both adipose tissue macrophages and T lymphocytes also contribute to formation of the inflammatory microenvironment in adipose tissue.

Interestingly, a large number of studies focus on the interplays between smoking and lymphocytes, so there is an emerging notion that smoking may mediate the numbers and functions of lymphocytes and the inflammation status within adipose tissue. According to existing research, it primarily utilizes the following pathways in the aforementioned pathological process.

First, certain cytokines and adipokines induced by smoking might influence the number and function of resident lymphocytes in adipose tissue, as well as local inflammation. For example, after activation of the NLRP3 inflammasome, enhanced CCL2 expression in perivascular adipocytes of smokers is previously discussed [78]. Notably, the stimulation by smoking or nicotine on macrophages was shown to further trigger adipose tissue inflammation. Through the Toll-like receptor 4 (TLR4), cigarette smoke induces phosphorylation of NF-κB in cultured macrophages to activate inflammatory signaling, resulting in more cytokines secretion [79]. Aside from these direct effects, increased FFAs on exposure to smoking can be recognized by TLR-4 to exert indirect actions. As shown in Table 1, adiponectin and leptin also participate in the phenotype transition, such as macrophage polarization and T lymphocytes [80, 81]. Hence, adipose tissue inflammation will in turn exacerbate the adventitia response and eventually deteriorate intima injury. Given these smoking-induced changes in adipose tissue, it is important to identify whether smoking is directly involved in the recruitment and activation of lymphocytes or not and what the potential mechanisms of involvement are.
6. Conclusion

There is a complex yet significant interaction between cigarette smoking exposure, adipose tissue, and atherosclerotic plaque formation and rupture. Smoking or nicotine appears to affect the differentiation and functions of adipocytes, as well as the inflammatory status in adipose tissue. The current literature has always shed light upon the multiple molecular mechanisms by which components of tobacco smoke can initiate endothelial injury. Of great interest is the complicated interaction between smoking and adipose tissue and how this could establish a better understanding of the course of smoking-related AS. However, there are few studies that provide direct evidences responsible for the e ect on adipose tissue by nicotine. Therefore, as the knowledge of nicotine-induced dysfunction in adipose tissue has advanced, it has become clear that there exists a “nicotine-adipose tissue-AS” axis, which paves the way for the development of further targeted therapy.

Abbreviations

AS: Atherosclerosis
AMPK: 5'-Monophosphate-activated protein kinase
BMI: Body mean index
CVDs: Cardiovascular diseases
cAMP: Cyclic adenosine monophosphate
FFAs: Free fatty acids
HSL: Hormone-sensitive lipase
IL: Interleukin
IFN: Interferon
LDL: Low-dense lipoprotein
nAChRs: Nicotinic acetylcholine receptors
NF-κB: Nuclear factor-kappa B
PPAR-γ: Peroxisome proliferator activated receptor-γ
PVAT: Perivascular adipose tissue
ROS: Reactive oxygen species
TLR4: Toll-like receptor 4
TNF: Tumor necrosis factor
VSMCs: Vascular smooth muscle cells.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

All authors contributed equally to the conception and design of the review, the analysis and interpretation of the literature, drafting the article, and approving the final version of the manuscript.

Acknowledgments

This work was supported by 81470471 from the Natural Science Foundation of China (NSFC).

References

[1] M. Ezzati, S. J. Henley, M. J. Thun, and A. D. Lopez, “Role of smoking in global and regional cardiovascular mortality,” Circulation, vol. 112, no. 4, pp. 489–497, 2005.
[2] J. Dratva, N. Probst-Hensch, A. Schmidt-Trucksäss et al., “Atherogenesis in youth—early consequence of adolescent smoking,” Atherosclerosis, vol. 230, no. 2, pp. 304–309, 2013.
[3] M. M. Finucane, G. A. Stevens, M. J. Cowan et al., “National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants,” The Lancet, vol. 377, no. 9765, pp. 557–567, 2011.
[4] Q. Huynh, L. Blizzard, J. Sharman et al., “Relative contributions of adiposity in childhood and adulthood to vascular health of young adults,” Atherosclerosis, vol. 228, no. 1, pp. 259–264, 2013.
[5] D. M. Freedman, A. J. Sigurdson, P. Rajaraman, M. M. Doody, M. S. Linet, and E. Ron, “The mortality risk of smoking and obesity combined,” American Journal of Preventive Medicine, vol. 31, no. 5, pp. 355–362, 2006.
[6] A. Koster, M. F. Leitzmann, A. Schatzkin et al., “The combined relations of adiposity and smoking on mortality,” American Journal of Clinical Nutrition, vol. 88, no. 5, pp. 1206–1212, 2008.
[7] R. Chatkin, J. M. Chatkin, L. Spanemberg, D. Casagrande, M. Wagner, and C. Mottin, “Smoking is associated with more abdominal fat in morbidly obese patients,” PLoS One, vol. 10, no. 5, article e0126146, 2015.
[8] Y. Wu, P. Song, W. Zhang et al., “Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo,” Nature Medicine, vol. 21, no. 4, pp. 373–382, 2015.
[9] H. Shimokata, D. C. Muller, and R. Andres, “Studies in the distribution of body fat. III. Effects of cigarette smoking,” JAMA, vol. 261, no. 8, pp. 1169–1173, 1989.
[10] M. Akbartabartoori, M. E. Lean, and C. R. Hankey, “Relationships between cigarette smoking, body size and body shape,” International Journal of Obesity, vol. 29, no. 2, pp. 236–243, 2005.
[11] I. Tabas, K. J. Williams, and J. Borén, “Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications,” Circulation, vol. 116, no. 16, pp. 1832–1844, 2007.
[12] A. J. Lusis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233–241, 2000.
[13] Y. V. Bobryshev, “Monocyte recruitment and foam cell formation in atherosclerosis,” Micron, vol. 37, no. 3, pp. 208–222, 2005.
[14] K. A. Campbell, M. J. Lipinski, A. C. Doran, M. D. Skafien, V. Fuster, and C. A. McNamara, “Lymphocytes and the adventitial immune response in atherosclerosis,” Circulation Research, vol. 110, no. 6, pp. 889–900, 2012.
[15] G. A. Payne, M. C. Kohr, and J. D. Tune, “Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease,” British Journal of Pharmacology, vol. 165, no. 3, pp. 659–669, 2012.
[16] D. Prefontaine, A. Morin, C. Jumarie, and A. Porter, “In vitro bioactivity of combustion products from 12 tobacco
constituents," Food Chemical Toxicology, vol. 44, no. 5, pp. 724–738, 2006.
[17] J. Lee and P. C. Cooke, "The role of nicotine in the pathogenesis of atherosclerosis," Atherosclerosis, vol. 215, no. 2, pp. 281–283, 2011.
[18] R. D. Eglet, K. C. Brown, and P. Dasgupta, "Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases," Pharmacology & Therapeutics, vol. 121, no. 2, pp. 205–223, 2009.
[19] H. Li, S. R. Srinivasan, W. Chen, J. H. Xu, S. Li, and G. S. Berenson, "Vascular abnormalities in asymptomatic, healthy young adult smokers without other major cardiovascular risk factors: the Bogalusa Heart Study," American Journal of Hypertension, vol. 18, no. 3, pp. 319–324, 2005.
[20] H. L. Luo, W. J. Zang, J. Lu, X. J. Yu, Y. X. Lin, and Y. X. Cao, "The protective effect of captopril on nicotine-induced endothelial dysfunction in rat," Basic Clinical Pharmacology & Toxicology, vol. 99, no. 3, pp. 237–245, 2006.
[21] C. Heeschen, M. Weis, and J. P. Cooke, "Nicotine promotes arteriogenesis," Journal of the American College of Cardiology, vol. 41, no. 3, pp. 489–496, 2003.
[22] M. S. Zhou, K. Chadipiralla, A. J. Mendez et al., "Nicotine potentiates prothrombotic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling," American Journal of Physiology: Heart and Circulatory Physiology, vol. 305, no. 4, pp. H563–H574, 2013.
[23] P. P. Lau, L. Li, A. J. Merched, A. L. Zhang, K. W. Ko, and L. Chan, "Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor−/− mice," Arteriosclerosis Thrombosis & Vascular Biology, vol. 26, no. 1, pp. 143–149, 2006.
[24] A. Cucina, P. Sapienza, V. Corvino et al., "Nicotine induces platelet-derived growth factor release and cytoskeletal alteration in aortic smooth muscle cells," Surgery, vol. 127, no. 1, pp. 72–78, 2000.
[25] A. Csordas and D. Bernhard, "The biology behind the atherothrombotic effects of cigarette smoke," Nature Reviews Cardiology, vol. 10, no. 4, pp. 219–230, 2013.
[26] S. Iwano, M. Nukaya, T. Saito, F. Asanuma, and T. Kamataki, "A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons," Biochemical and Biophysical Research Communications, vol. 335, no. 1, pp. 220–226, 2005.
[27] G. Siasos, V. Tsikgou, E. Kokkou et al., "Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches," Current Medicinal Chemistry, vol. 21, no. 34, pp. 3936–3948, 2014.
[28] D. C. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma, "Adipokines: molecular links between obesity and atherosclerosis," American Journal of Physiology Heart & Circulatory Physiology, vol. 288, no. 5, pp. H2031–H2041, 2005.
[29] J. J. Fuster, N. Ouchi, N. Gokce, and K. Walsh, "Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease," Circulation Research, vol. 118, no. 11, pp. 1786–1807, 2016.
[30] B. Klop, J. W. Elte, and M. C. Cabezas, "Dyslipidemia in obesity: mechanisms and potential targets," Nutrition, vol. 5, no. 4, pp. 1218–1240, 2013.
[31] Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, "Positional cloning of the mouse obese gene and its human homologue," Nature, vol. 372, no. 6505, pp. 425–432, 1994.
[32] M. W. Rajala, Y. Qi, H. R. Patel et al., "Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting," Diabetes, vol. 53, no. 7, pp. 1671–1679, 2004.
[33] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, "Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance," Science, vol. 259, no. 5091, pp. 87–91, 1993.
[34] Y. Arita, S. Kihara, N. Ouchi et al., "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity," Biochemical & Biophysical Research Communications, vol. 257, no. 1, pp. 79–83, 1999.
[35] D. S. B. Cm, R. Z. Yang, M. J. Lee et al., "Omentin plasma levels and gene expression are decreased in obesity," Diabetes, vol. 56, no. 6, pp. 1655–1661, 2007.
[36] K. H. Cheng, C. S. Chu, K. T. Lee et al., "Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease," International Journal of Obesity, vol. 32, no. 2, pp. 268–274, 2008.
[37] Y. H. Jin, Y. J. Park, M. Ham, and J. B. Kim, "Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity," Molecules and Cells, vol. 37, no. 5, pp. 365–371, 2014.
[38] Y. J. Gao, "Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/ lipodystrophy-related vascular dysfunction," Current Pharmaceutical Design, vol. 13, no. 21, pp. 2185–2192, 2007.
[39] K. Rittig, J. H. Dolderer, B. Balletschöfer et al., "The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells," Diabetologia, vol. 55, no. 5, pp. 1514–1525, 2012.
[40] C. Gotti, E. Carbonnelle, M. Moretti, R. Zwart, and F. Clemenzi, "Drugs selective for nicotinic receptor subtypes: a real possibility or a dream?," Behavioural Brain Research, vol. 113, no. 1-2, pp. 183–192, 2000.
[41] R. Cancello, A. Zulian, S. Maestroni et al., "The nicotinic acetylcholine receptor α7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by diet-induced weight loss," International Journal of Obesity, vol. 36, no. 12, pp. 1552–1557, 2012.
[42] K. Andersson and P. Arner, "Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors," International Journal of Obesity, vol. 25, no. 8, pp. 1225–1232, 2001.
[43] V. Narayanawami, S. S. Somkuwar, D. B. Horton, L. A. Cassis, and L. P. Dwoskin, "Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked [3H]dopamine and [3H]norepinephrine release," Biochemical Pharmacology, vol. 86, no. 5, pp. 656–665, 2013.
[44] L. Azam and J. M. McIntosh, "Characterization of nico- tic acetylcholine receptors that modulate nicotine-evoked [3H]norepinephrine release from mouse hippocampal synaptosomes," Molecular Pharmacology, vol. 70, no. 3, pp. 967–976, 2006.
[45] H. M. Schuller, P. K. Tithof, M. Williams, and H. Plummer 3rd, "The tobacco-specific carcinogen 4-(methyl nitrosa- mino)-1-(3-pyridyl)-1-butaneone is a β-adrenergic agonist and stimulates DNA synthesis in lung adenosarcoma via β-adrenergic receptor-mediated release of arachidonic acid," Cancer Research, vol. 59, no. 18, pp. 4510, 1999.
[46] M. Alexandre, A. K. Uduman, S. Minervini et al., “Tobacco carcinogen 4-(methyl nitrosamino)-1-(3-pyridyl)-1-butanone initiates and enhances pancreatitis responses,” American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 303, no. 6, pp. G696–G704, 2012.

[47] P. K. Tithof, M. Elgayyar, H. M. Schuller, M. Barnhill, and R. Andrews, “4-(Methyl nitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine derivative, induces apoptosis of endothelial cells,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 281, no. 5, pp. H1946–H1954, 2001.

[48] W. Cao, A. V. Medvedev, K. W. Daniel, and S. Collins, “β-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase,” Journal of Biological Chemistry, vol. 276, no. 29, pp. 27077–27082, 2001.

[49] M. Fasshauer, J. Klein, S. Neumann, M. Eszlinger, and R. Paschke, “Adiponectin gene expression is inhibited by β-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes,” FEBS Letters, vol. 507, no. 2, pp. 142–146, 2001.

[50] A. Chiolerio, D. Faeh, F. Paccaud, and J. Cornuz, “Consequences of smoking for body weight, body fat distribution, and insulin resistance,” The American Journal of Clinical Nutrition, vol. 87, no. 4, pp. 801–809, 2008.

[51] E. de Oliveira, E. G. Moura, A. P. Santos-Silva et al., “Neonatal nicotine exposure causes insulin and leptin resistance and inhibits hypothalamic leptin signaling in adult rat offspring,” Endocrinology, vol. 206, no. 1, pp. 55–63, 2010.

[52] E. Somm, V. M. Schwitzgebel, D. M. Vauthay et al., “Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life,” Endocrinology, vol. 149, no. 12, pp. 6289–6299, 2008.

[53] T. Yamauchi, J. Kamon, H. Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance,” Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001.

[54] P. D. G. Miles, Y. Barak, W. He, R. M. Evans, and J. M. Olefsky, “Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency,” Journal of Clinical Investigation, vol. 105, no. 3, pp. 287–292, 2000.

[55] D. Ren, T. N. Collingwood, E. J. Rebar, A. P. Wolffe, and H. S. Camp, “PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1reactivates adipogenesis,” Genes & Development, vol. 16, no. 1, pp. 27–32, 2002.

[56] Z. An, H. Wang, P. Song, M. Zhang, X. Geng, and M. H. Zou, “Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress,” Journal of Biological Chemistry, vol. 282, no. 37, pp. 26793–26801, 2007.

[57] M. Ioth, T. Tsuji, H. Nakamura et al., “Systemic effects of acute cigarette smoke exposure in mice,” Inhalation Toxicology, vol. 26, no. 8, pp. 464–473, 2014.

[58] H. Lee, Y. J. Lee, H. Choi, E. H. Ko, and J. Kim, “Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion,” Journal of Biological Chemistry, vol. 284, no. 16, pp. 10601–10609, 2009.

[59] P. A. Hosick, A. A. AlAmodi, M. V. Storm et al., “Chronic carbon monoxide treatment attenuates development of obesity and remodels adipocytes in mice fed a high-fat diet,” International Journal of Obesity, vol. 38, no. 1, pp. 132–139, 2014.

[60] P. Irigaray, S. Lacomme, L. Mejean, and D. Belpomme, “Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons,” Toxicology Letters, vol. 187, no. 1, pp. 35–39, 2009.

[61] J. H. Kim, K. Yamaguchi, S. H. Lee et al., “Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors,” Toxicological Sciences, vol. 85, no. 1, pp. 585–593, 2005.

[62] H. E. Bays, “Adiposopathy is “sick fat” a cardiovascular disease?,” Journal of the American College of Cardiology, vol. 57, no. 25, pp. 2461–2473, 2011.

[63] D. Langin, “Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome,” Pharmacological Research, vol. 53, no. 6, pp. 482–491, 2006.

[64] Y. Iwashima, T. Katsuya, K. Ishikawa et al., “Association of hypoadiponectinemia with smoking habit in men,” Hypertension, vol. 45, no. 6, pp. 1094–1100, 2005.

[65] S. Bergmann and R. Siekmie, “Influence of smoking and body weight on adipokines in middle aged women,” European Journal of Medical Research, vol. 14, Supplement 4, pp. 21–26, 2009.

[66] K. Parisi, L. Tsanoumis, and A. Kafouri, “Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population,” Atherosclerosis, vol. 205, no. 2, pp. 632–636, 2009.

[67] M. Li, C. Li, Y. Liu et al., “Decreased secretion of adiponectin through its intracellular accumulation in adipose tissue during tobacco smoke exposure,” Nutrition & Metabolism, vol. 12, no. 1, p. 15, 2014.

[68] K. Merz-Atalik, “Tyra, Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by both nicotine and nACh receptors containing the β2 subunit,” Molecular Genetics & Metabolism, vol. 107, no. 3, pp. 561–570, 2012.

[69] M. L. Delporte, T. Funahashi, M. Takahashi, Y. Matsuzawa, and S. M. Brichard, “Pre- and post-translational negative effect of β-adrenergic agonists on adiponectin secretion: in vitro and in vivo studies,” Biochemical Journal, vol. 367, Part 3, pp. 677–685, 2002.

[70] N. Maeda, I. Shimomura, K. Kishida et al., “Diet-induced insulin resistance in mice lacking adiponectin/ACRP30,” Nature Medicine, vol. 8, no. 7, pp. 731–737, 2002.

[71] L. Mach, H. Bedanova, M. Soucek, M. Karpisek, P. Nemec, and M. Orban, “Tobacco smoking and cytokine levels in human epicardial adipose tissue: impact of smoking cessation,” Atherosclerosis, vol. 255, pp. 37–42, 2016.

[72] M. Ryden, A. Dicker, V. van Harmelen et al., “Mapping of early signaling events in tumor necrosis factor-a-mediated lipolysis in human fat cells,” Journal of Biological Chemistry, vol. 277, no. 2, pp. 1085–1091, 2002.

[73] R. H. Liu, M. Mizuta, and S. Matsukawa, “The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes,” The Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 1, pp. 52–58, 2004.

[74] J. L. Nobre, P. C. Lisboa, A. P. Santos-Silva et al., “Calcium supplementation reverses central adiposity, leptin, and insulin resistance in adult offspring programed by neonatal nicotine...
exposure,” *Journal of Endocrinology*, vol. 210, no. 3, pp. 349–359, 2011.

[75] G. Targher, L. Zenari, G. Facci, G. Falezza, M. Muggeo, and G. Zoppini, “Serum leptin concentrations in young smokers with type 1 diabetes,” *Diabetes Care*, vol. 24, no. 4, pp. 793–794, 2001.

[76] J. E. Reseland, H. H. Mundal, K. Hollung et al., “Cigarette smoking may reduce plasma leptin concentration via catecholamines,” *Prostaglandins Leukotrienes and Essential Fatty Acids*, vol. 73, no. 1, pp. 43–49, 2005.

[77] K. A. Perkins and C. Fonte, “Effects of smoking status and smoking cessation on leptin levels,” *Nicotine & Tobacco Research*, vol. 4, no. 4, pp. 459–466, 2002.

[78] C. Rossi, E. Santini, M. Chiarugi et al., “The complex P2X7 receptor/inflamasome in perivascular fat tissue of heavy smokers,” *European Journal of Clinical Investigation*, vol. 44, no. 3, pp. 295–302, 2013.

[79] K. Karimi, H. Sarir, E. Mortaz et al., “Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages,” *Respiratory Research*, vol. 7, no. 1, p. 66, 2006.

[80] K. Ohashi, J. L. Parker, N. Ouchi et al., “Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype,” *Journal of Biological Chemistry*, vol. 285, no. 9, pp. 6153–6160, 2010.

[81] G. M. Lord, G. Matarese, J. K. Howard, R. J. Baker, S. R. K. Ohashi, J. L. Parker, N. Ouchi et al., “Adiponectin, an adipocyte-derived plasma protein, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages,” *Circulation*, vol. 103, no. 8, pp. 1057–1063, 2001.

[82] Y. Arita, S. Kihara, N. Ouchi et al., “Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell,” *Circulation*, vol. 105, no. 24, pp. 2893–2898, 2002.

[83] G. S. Hotamisligil, A. Budavari, D. Murray, and B. M. Spiegelman, “Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha,” *Journal of Clinical Investigation*, vol. 94, no. 4, pp. 1543–1549, 1994.

[84] P. Kleinbongard, G. Heusch, and R. Schulz, “TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure,” *Pharmacology & Therapeutics*, vol. 127, no. 3, pp. 295–314, 2010.

[85] J. J. Boyle, P. L. Weissberg, and M. R. Bennett, “Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms,” *Arteriosclerosis Thrombosis & Vascular Biology*, vol. 23, no. 9, pp. 1553–1558, 2003.

[86] H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, “Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells,” *Biochemical and Biophysical Research Communications*, vol. 408, no. 2, pp. 339–343, 2011.

[87] S. Maruyama, R. Shibata, R. Kikuchi et al., “Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism,” *Journal of Biological Chemistry*, vol. 287, no. 1, pp. 408–417, 2012.

[88] J. M. Northcott, A. Yeganeh, C. G. Taylor, P. Zahradka, and J. T. Wigle, “Adipokines and the cardiovascular system: mechanisms mediating health and disease,” *Canadian Journal of Physiology and Pharmacology*, vol. 90, no. 8, pp. 1029–1059, 2012.

[89] H. Kobayashi, N. Ouchi, S. Kihara et al., “Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin,” *Circulation Research*, vol. 94, no. 4, pp. e27–e31, 2004.

[90] N. Ouchi, S. Kihara, Y. Arita et al., “Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-κB signaling through a CAMP-dependent pathway,” *Circulation*, vol. 102, no. 11, pp. 1296–1301, 2000.

[91] N. Ouchi, S. Kihara, Y. Arita et al., “Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages,” *Circulation*, vol. 103, no. 8, pp. 1057–1063, 2001.

[92] Y. Arita, S. Kihara, N. Ouchi et al., “Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell,” *Circulation*, vol. 105, no. 24, pp. 2893–2898, 2002.

[93] G. S. Hotamisligil, A. Budavari, D. Murray, and B. M. Spiegelman, “Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha,” *Journal of Clinical Investigation*, vol. 94, no. 4, pp. 1543–1549, 1994.

[94] P. Kleinbongard, G. Heusch, and R. Schulz, “TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure,” *Pharmacology & Therapeutics*, vol. 127, no. 3, pp. 295–314, 2010.

[95] J. J. Boyle, P. L. Weissberg, and M. R. Bennett, “Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms,” *Arteriosclerosis Thrombosis & Vascular Biology*, vol. 23, no. 9, pp. 1553–1558, 2003.

[96] H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, “Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells,” *Biochemical and Biophysical Research Communications*, vol. 408, no. 2, pp. 339–343, 2011.

[97] S. Maruyama, R. Shibata, R. Kikuchi et al., “Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism,” *Journal of Biological Chemistry*, vol. 287, no. 1, pp. 408–417, 2012.

[98] J. M. Northcott, A. Yeganeh, C. G. Taylor, P. Zahradka, and J. T. Wigle, “Adipokines and the cardiovascular system: mechanisms mediating health and disease,” *Canadian Journal of Physiology and Pharmacology*, vol. 90, no. 8, pp. 1029–1059, 2012.
[103] T. S. Lee, C. Y. Lin, J. Y. Tsai et al., “Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages,” Life Sciences, vol. 84, no. 3-4, pp. 97–104, 2009.

[104] J. B. Boord, K. Maeda, L. Makowski et al., “Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice,” Circulation, vol. 110, no. 11, pp. 1492–1498, 2004.

[105] L. Makowski, J. B. Boord, K. Maeda et al., “Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis,” Nature Medicine, vol. 7, no. 6, pp. 699–705, 2001.

[106] R. Hart and D. R. Greaves, “Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5,” The Journal of Immunology, vol. 185, no. 6, pp. 3728–3739, 2010.